Mortality rates from Creutzfeldt-Jakob disease (CJD)

Ladogana et al. analyzed the available data on 4,441 cases of CJD provided from an international study. The overall annual mortality rate for sporadic CJD was 1.39 per million, with similar figures in all participating countries. Mortality rates differed for genetic, iatrogenic, and variant CJD.

see page 1586

PRNP analysis is crucial for genetic transmissible spongiform encephalopathies diagnosis

Ladogana et al. sequenced the *PRNP* gene in 643 cases with suspected human transmissible spongiform encephalopathies (TSE) and found that 130 cases carried pathogenic mutations. About 60% of them had no relatives with TSE and had clinical and laboratory findings comparable to sporadic Creutzfeldt-Jakob disease. Genetic TSE patients would have been misclassified without *PRNP* gene analysis.

see page 1592

Cholesterol and dementia

Dufouil et al. evaluated the association of cholesterol levels, lipid-lowering agent (LLA) intake, and *APOE* genotype with dementia prevalence in a population-based study of 9,294 subjects. LLA intake was associated with decreased risk of dementia whereas hyperlipidemia was associated with increased odds for non-AD type dementia.

see page 1531

A β immunization in patients with Alzheimer disease

Gilman et al. studied A β immunization in 372 patients with AD. Although the trial was interrupted because of meningoencephalitis in 6% of immunized patients, cognitive performance was better and CSF tau levels were lower in antibody responders than placebo cases, suggesting a downstream neuropathologic benefit of targeting A β .

see page 1553

The accompanying article by Fox et al. reports on cerebral volume changes in antibody responders from the same study. Responders had greater brain volume loss but better cognitive performance compared to placebo cases. The volume loss in responders may be due in part to amyloid removal.

see page 1563

Migraine with aura and ischemic stroke

Stang et al. studied the association of migraine with ischemic stroke in 12,750 middle-aged adults. Those with a history of migraine accompanied by aura had a higher occurrence of ischemic stroke. In contrast, there was little association between migraine without aura and ischemic stroke.

see page 1573

The editorial by Diener and Kurth concludes that there is good evidence that migraine with aura is associated with an increased risk of ischemic stroke, which appears to be stronger among the young but may persist in the elderly. Prospective data do not support an association between migraine without aura and ischemic stroke. Strict definitions of migraine and stroke as well as a prospective assessment of the migraine-stroke association are essential.

see page 1496

■ The ability of persons with AD to make a decision about using treatment for AD

Karlawish et al. studied the ability of persons with mild to moderate stage Alzheimer disease (AD) to understand and appreciate the risks and benefits involved in the decision to take an AD-slowing medication. They found that impairments in these abilities as well as in the process of reasoning that flows from them was significant among persons with moderate stage dementia and those who lacked awareness of their diagnosis, symptoms, or prognosis. Such persons were more likely to be judged not competent.

see page 1514

Who can say yes (or no) to a physician and how does the physician know they can?

The accompanying editorial by McQuillen and Tariot notes that an essential message from this study is one of sensitivity, respect, and humility: sensitivity to the dimensions of a multifaceted illness such as dementia; respect for persons, even when demented; and humility in recognizing the degree to which a bond of trust influences decision-making. The authors show us that the mere presence of a dementia diagnosis does not preclude the patient from participating in decisions about his or her own care.

see page 1494

■ Use of tacrolimus in myasthenia gravis

Ponseti et al. present the long-term results of tacrolimus in 79 cyclosporine- and prednisone-dependent patients with myasthenia gravis. Ninety-two percent of patients had received tacrolimus for more than 3 years. Tacrolimus was well-tolerated and did not have major adverse effects related to long-term treatment. All but two patients were withdrawn from prednisone.

see page 1641

■ Ventriculoperitoneal shunt for leptomeningeal metastasis

Omuro et al. reviewed patients with leptomeningeal metastasis and found they frequently developed intracranial hypertension and often had hydrocephalus. Shunting rapidly relieved symptoms of intracranial hypertension; median survival was only 2 months after shunt but some of the patients survived for years.

see page 1625

■ Orthotic device effective in primary writing tremor

A writing device significantly benefited drawing and writing in patients with primary writing tremor. Espay et al. suggest applying this simple, noninvasive intervention before pharmacotherapy or functional surgery in task-specific tremor.

see page 1648

NEUROLOGY INVITES "CLINICAL TRIALS RECRUITING" ANNOUNCEMENTS

Neurology now publishes a "Clinical Trials Recruiting" print and online section. This section is prominently displayed on the cover, in the Table of Contents, and on the *Neurology* Web site home page.

Neurology has the widest readership of any neurological journal, and *Neurology* online receives heavy traffic from the public. This online section has open access and is featured on the *Neurology* home page.

Line ads can be placed at no charge and display ads [full or 1/2 page] can also be placed for a fee. The ad must be IRB approved before submission. Contact ctrecruiting@urmc.rochester.edu or click on "Clinical Trials Recruiting" on the home page [www.neurology.org] for more information.

Neurology®

May 10 Highlights

Neurology 2005;64;1492-1493

DOI 10.1212/WNL.64.9.1492

This information is current as of May 9, 2005

Updated Information & Services

including high resolution figures, can be found at:
<http://n.neurology.org/content/64/9/1492.full>

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints

Information about ordering reprints can be found online:
<http://n.neurology.org/subscribers/advertise>

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.